Endo International PLC (NASDAQ:ENDP)’s share price traded down 2.1% on Thursday . The stock traded as low as $21.53 and last traded at $21.63, with a volume of 6,063,861 shares trading hands. The stock had previously closed at $22.09.

A number of research firms have recently commented on ENDP. Mizuho upgraded Endo International PLC from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $16.00 to $29.00 in a research note on Friday, August 12th. Vetr lowered Endo International PLC from a “hold” rating to a “strong sell” rating and set a $18.21 price objective on the stock. in a research note on Tuesday, August 9th. JPMorgan Chase & Co. set a $40.00 price objective on Endo International PLC and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Piper Jaffray Cos. set a $19.00 price objective on Endo International PLC and gave the stock a “hold” rating in a research note on Tuesday, August 9th. Finally, Leerink Swann reiterated a “hold” rating and issued a $22.00 price objective (down from $23.00) on shares of Endo International PLC in a research note on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $39.78.

The stock’s 50-day moving average price is $19.49 and its 200-day moving average price is $25.86. The stock’s market capitalization is $4.68 billion.

Endo International PLC (NASDAQ:ENDP) last issued its earnings results on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.12. The firm earned $921 million during the quarter, compared to the consensus estimate of $873.50 million. During the same period in the previous year, the company posted $1.08 earnings per share. The firm’s revenue for the quarter was up 25.3% compared to the same quarter last year. On average, equities analysts forecast that Endo International PLC will post $4.56 EPS for the current fiscal year.

A number of hedge funds and institutional investors recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. boosted its position in Endo International PLC by 350.9% in the fourth quarter. Ameriprise Financial Inc. now owns 2,458,860 shares of the company’s stock valued at $150,532,000 after buying an additional 1,913,553 shares in the last quarter. RS Investment Management Co. LLC boosted its position in Endo International PLC by 29.5% in the fourth quarter. RS Investment Management Co. LLC now owns 543,593 shares of the company’s stock valued at $33,279,000 after buying an additional 123,692 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock valued at $16,737,000 after buying an additional 12,234 shares in the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.